Timberlyne Therapeutics
Ajay Duggal, MB ChB, MRCP, Dip Pharm Med, currently serves as Interim Chief Medical Officer at Timberlyne Therapeutics and Acting Chief Medical Officer at PriveBio, with a notable history in leadership roles within the biotech and startup sectors. Since November 2014, Ajay Duggal has been the Managing Director at Adnovate Clinical, providing CMO-level and medical consultancy services across various therapy areas, including biologics, small molecules, and digital health solutions. Previous positions include Interim CMO roles at multiple organizations such as GexVal, ENDPOINT HEALTH, and Race Oncology, as well as Chief Medical Officer at TOPIVERT LIMITED, where responsibilities included overseeing clinical strategy and participating in fundraising efforts. Ajay Duggal earned a Doctor of Medicine degree from The University of Sheffield and holds an MRCP from the Royal College of Physicians in the UK.
This person is not in any teams
This person is not in any offices
Timberlyne Therapeutics
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.